Results 241 to 250 of about 96,322 (259)

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs

Annals of Oncology, 2021
Enriqueta Felip, Alessandra Bearz, Benjamin J Solomon   +2 more
exaly  

Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC

Lung Cancer, 2021
Misako Nagasaka, Sai-Hong Ou, Viola W Zhu   +2 more
exaly  

Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

Journal of Thoracic Oncology, 2021
Ji-Youn Han, Dong-Wan Kim, Hye Ryun Kim
exaly  

Differential protein stability and clinical responses ofEML4-ALK fusion variants to various ALK inhibitors in advancedALK-rearranged non-small cell lung cancer

Annals of Oncology, 2017
Richard Bayliss, Mark W. Richards, J Y Song   +2 more
exaly  

Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK ‘borderline’-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies

Annals of Oncology, 2015
Charles Marquette, Paul Hofman, Jérôme Mouroux   +2 more
exaly  

ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma

Annals of Oncology, 2012
Charles Marquette, Marius Ilié, Paul Hofman   +2 more
exaly  

Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer

Annals of Oncology, 2013
Daniel B Costa, Valentina Monica, J A Engelman   +2 more
exaly  

Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor

Annals of Oncology, 2015
B Keam, J Koh, D H Chung
exaly  

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC

Annals of Oncology, 2014
C H Bartlett, G J Riely, G A Otterson
exaly  

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

Annals of Oncology, 2018
Anna Kron, Matthias Scheffler, J Fassunke   +2 more
exaly